OOIR: Observatory of International Research

Papers

(The TQCC of JACC: Cardiooncology is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Full Issue PDF	162
Priorities in Cardio-Oncology	160
Atrial Fibrillation in Patients With Cancer	120
Full Issue PDF	101
To Anticoagulate or Not to Anticoagulate to Prevent Arterial Thrombosis During Systemic Cancer Therapy	94
Full Issue PDF	92
Epigenomics of Cardio-Oncology	91
LAG3 Blockade Expands T Cells Within Atherosclerotic Plaque	83
Hormonal Therapy and Cardiovascular Health	76
Cancer Therapy and Exercise Intolerance: The Heart Is But a Part	73
Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors	72
Deep Inspiration Breath Hold in Left-Sided Breast Radiotherapy	71
Cardiovascular Safety in Oncology Clinical Trials	70
Prospective Screening for Transthyretin Cardiac Amyloidosis in Spinal Stenosis Surgery Patients	63
Balancing Promise and Evidence	62
SGLT2i and Primary Prevention of Cancer Therapy–Related Cardiac Dysfunction in Patients With Diabetes	61
Moving the Pendulum for Earlier Detection of Systolic and Diastolic Dysfunction in Cancer Survivors	58
Full Issue PDF	54
Assessing Neurohormonal Antagonist Withdrawal in HER2+ Breast Cancer Patients With CTRCD	54
Prevalence, Treatment, and Prognosis of Tumor Thrombi in Renal Cell Carcinoma	49
Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy	48
Cardiac Risk Stratification Before Lung Cancer Radiation	47
Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients	47
Long-Term, Implantable Event Monitoring of Patients With Wild-Type Transthyretin Cardiac Amyloidosis	45
Risk Prediction in Cardio-Oncology: Conceptual and Methodological Considerations	43

Proactive Surveillance for ICI Cardiotoxicity	42
Incretin Mimetics in Cancer and Cardiovascular Disease	41
Atorvastatin Does Not Attenuate Aortic Stiffening After Doxorubicin for Breast Cancer and Lymphoma (PREVENT-WF-98213)	38
Beyond Thrombosis: Pulmonary Hypertension and Heart Failure in Patients With Myeloproliferative Neoplasms	38
Frailty	38
Editorial Board/Officers Page	38
Cardiac Substructure Radiation Dose and Associations With Tachyarrhythmia and Bradyarrhythmia After Lung Cancer Radiotherapy	38
Atrial Fibrillation After Stem Cell Transplantation	36
Peripheral Ischemia Fuels Breast Cancer Via Myeloid-Skewed Hematopoiesis	36
Cancer Immunotherapy Beyond Checkpoint Blockade	36
Full Issue PDF	34
Permissive Cardiotoxicity	34
Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillance	33
Clonal Hematopoiesis in Cancer and Cardiovascular Disease	33
Successful CAR T Cell Therapy in a Heart and Kidney Transplant Recipient With Refractory PTLD	32
Changes in Physical Activity and Cardiovascular Disease Risk in Cancer Survivors	31
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients	31
Correlation of Natriuretic Peptides with Invasively Measured Intracardiac Filling Pressures in Patients With Cancer	30
Full Issue PDF	30
The Association of Malignancy With Stroke and Bleeding in Atrial Fibrillation	29
Involvement of Rho-Associated Coiled-Coil Containing Kinase (ROCK) in BCR-ABL1 Tyrosine Kinase Inhibitor Cardiovascular Toxicity	29
Leveling Up	29
Editorial Board	28
Coronary Artery Calcium Scores After Prophylactic Premenopausal Bilateral Salpingo-Oophorectomy	28
Developing a Model for Cross-Institutional Educational Collaborations	28
Endothelin-1	28
Mismatch Between Preclinical Cardio-Oncology and Clinical Oncology Research	27
Circulating MicroRNA as Biomarkers of Anthracycline-Induced Cardiotoxicity	27
Reply	27
Outcomes of Patients With Myeloproliferative Neoplasms Admitted With Myocardial Infarction	26
Artificial Intelligence to Complement, Not Replace, Clinical Knowledge	26
Quality-of-Care Measures for Cardio-Oncology	26
Dantrolene as a Potential Strategy to Prevent Doxorubicin-Induced Cardiotoxicity	26
Full Issue PDF	25
Enalapril for Preventing Cardiotoxicity After High-Dose Anthracycline Therapy in Breast Cancer and Lymphoma Patients	25
Genetic Testing in Evaluating Risk of Anthracycline Cardiomyopathy	25
Imaging Immune Checkpoint Inhibitor Myocarditis	24
Vascular Complications of Atrial Fibrillation in Patients With Cancer	24
CHA2DS2-VASc Score in Cardio-Oncology	24
Low QRS Voltages in Cardiac Amyloidosis	23
Deep Inspiration Breath Hold to Reduce Cardiovascular Disease Risk for Breast Radiotherapy	23
Endoplasmic Reticulum Selective Autophagy Alleviates Anthracycline-Induced Cardiotoxicity	23
Prognosis of MPN Patients Experiencing Acute Thrombotic Events and the Potential Role of Cytoreduction	23
Fluoropyrimidine Therapy in Gastrointestinal Cancer	23
Racial and Ethnic Disparities in All-Cause and Cardiovascular Mortality Among Cancer Patients in the U.S.	23
High-Sensitivity Troponin I	22
Heart Failure Readmission in Patients With ST-Segment Elevation Myocardial Infarction and Active Cancer	22
Diet and Prevention of Cardiovascular Disease and Cancer	22
The United Kingdom’s First Cardio-Oncology Service	22
Baseline Cardiac Parameters as Biomarkers of Radiation Cardiotoxicity in Lung Cancer	21

Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction	21
Cardiovascular Toxicities of BTK Inhibitors in Chronic Lymphocytic Leukemia	21
Incident Myocardial Infarction, Heart Failure, and Oncologic Outcomes in Breast Cancer Survivors	20
Reply	20
FULL ISSUE PDF	20
Cancer Therapy–Related Cardiac Dysfunction	20
To Adjudicate or Not Adjudicate	20
Hearts on the Minds of Oncologists	19
A New Risk Factor for Cardiovascular Events in Patients Receiving Immune Checkpoint Inhibitor Therapy?	19
Harnessing iPSCs to Dissect Causality in Anthracycline-Induced Cardiotoxicity	19
Association of Midlife Cardiovascular Health and Subsequent Change in Cardiovascular Health With Incident Cancer	19
Full Issue PDF	19
Optimal Timing of a Physical Exercise Intervention to Improve Cardiorespiratory Fitness	18
Second Malignancies and Cardiovascular Disease in Childhood Cancer Survivors	18
Cardiovascular Risk Assessment in Patients With Kidney Cancer	17
Cardiogenic Shock From Chronic Immune Checkpoint Inhibitor Associated Myocarditis Causing Predominant Right Ventricular Failure	17
Cardiovascular Considerations After Cancer Therapy	17
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors	17
What Is the Evidence of the Diagnostic Criteria and Screening of Immune Checkpoint Inhibitor–Induced Myocarditis?	17
Cardiovascular Care After Cancer	16
Redefining Gamification for Cardiovascular Prevention in High-Risk Cancer Survivors	16
Navigating the Uncharted	16
Guiding Treatment With Recovered CTRCD	16
A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid Cardiomyopathy	16
Clinical Practice Guidelines in Cardio-Oncology	15
Evaluating Anticoagulant Strategies for Atrial Fibrillation in Patients With Cancer	15
Reply	15
Preventing Cancer Therapy–Related Cardiotoxicity	14
Reassessing Troponin Surveillance in Immunotherapy	14
Physical Activity and Cardiac Function in Long-Term Breast Cancer Survivors	14
Editorial Board	14
Addressing the Overlooked	14
Reply	14
Reply	14
The Cause of Death in Patients With Cancer	14
(Less) Time and Energy	14
Impact of Pre-Existing Frailty on Cardiotoxicity Among Breast Cancer Patients Receiving Adjuvant Therapy	13
The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity	13
Learning From Trials	13
Racial Differences in Chronic Stress/Allostatic Load Variation Due to Androgen Deprivation Therapy in Prostate Cancer	13
Postural Orthostatic Tachycardia Syndrome and Orthostatic Hypotension Following Hematopoietic Stem Cell Transplantation	13
Editorial Board/Officers Page	13
Considerations of Competing Risks Analysis in Cardio-Oncology Studies	13
Full Issue PDF	12
Cancer Diagnosis, Physical Activity, and Heart Disease Risk	12
Overcoming LGBTQI+ Disparities in Cardio-Oncology	12
When Clot Is Tumor	12
Anticoagulation for the Prevention of Arterial Thrombosis in Ambulatory Cancer Patients	12
Genomics for Improving Heart Failure Risk Assessment in Cancer Patients	12
The ESC Cardio-Oncology Guidelines	12
A Biomarker-Based Diagnostic Model for Cardiac Dysfunction in Childhood Cancer Survivors	12
Full Issue PDF	12
Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology	12
Editorial Board	12
High-Sensitivity Cardiac Troponin I for Long-Term Cardiovascular Risk Stratification in a Cancer Clinic Population	12
Reply	12
Genetic Susceptibility for Anthracycline-Induced Cardiomyopathy	12
Reply	11
Assessing STEMI Outcomes in Patients With Cancer	11
LAG3 Regulates T Cell Activation and Plaque Infiltration in Atherosclerotic Mice	11
Predicting Left Ventricular Dysfunction in Childhood Cancer Survivors	11
Cardiotoxicity of BRAF/MEK Inhibitors According to HFA/ICOS Cardiotoxicity Risk Category	11
Growing, Building, and Defining the Field of Cardio-Oncology for Our Patients	11
Reply	11
ROCK and Rolling Towards Predicting BCR-ABL Kinase Inhibitor-Induced Vascular Toxicity	11
The Association of Metformin With Heart Failure in Patients With Diabetes Mellitus Receiving Anthracycline Chemotherapy	11